Ceren Durer

440 total citations
30 papers, 280 citations indexed

About

Ceren Durer is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Ceren Durer has authored 30 papers receiving a total of 280 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hematology, 9 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Ceren Durer's work include Multiple Myeloma Research and Treatments (8 papers), Acute Myeloid Leukemia Research (4 papers) and Protein Degradation and Inhibitors (4 papers). Ceren Durer is often cited by papers focused on Multiple Myeloma Research and Treatments (8 papers), Acute Myeloid Leukemia Research (4 papers) and Protein Degradation and Inhibitors (4 papers). Ceren Durer collaborates with scholars based in United States. Ceren Durer's co-authors include Seren Durer, Faiz Anwer, Muhammad Junaid Tariq, Warda Faridi, Saad Ullah Malik, Ali Younas Khan, Ali McBride, Abdul Rafae, Zeeshan Ali and Atlantis Dawn Russ and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Ceren Durer

24 papers receiving 277 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ceren Durer United States 8 141 134 69 69 49 30 280
Seren Durer United States 8 141 1.0× 134 1.0× 66 1.0× 68 1.0× 49 1.0× 29 273
Christin B. DeStefano United States 10 138 1.0× 147 1.1× 99 1.4× 59 0.9× 50 1.0× 30 292
Liya Ma China 11 93 0.7× 121 0.9× 107 1.6× 27 0.4× 53 1.1× 39 305
Kazunari Aoki Japan 11 101 0.7× 172 1.3× 32 0.5× 49 0.7× 71 1.4× 24 302
R. Erttmann Germany 9 112 0.8× 190 1.4× 42 0.6× 58 0.8× 46 0.9× 16 344
Trevor Shields France 4 149 1.1× 275 2.1× 28 0.4× 76 1.1× 26 0.5× 6 347
Ruemu Birhiray United States 8 80 0.6× 71 0.5× 50 0.7× 51 0.7× 80 1.6× 32 241
L.F. Porrata United States 5 160 1.1× 212 1.6× 39 0.6× 168 2.4× 80 1.6× 7 355
Teeraya Puavilai Thailand 8 142 1.0× 85 0.6× 43 0.6× 80 1.2× 178 3.6× 23 322
Guy Cantin Canada 9 97 0.7× 159 1.2× 29 0.4× 48 0.7× 56 1.1× 23 276

Countries citing papers authored by Ceren Durer

Since Specialization
Citations

This map shows the geographic impact of Ceren Durer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ceren Durer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ceren Durer more than expected).

Fields of papers citing papers by Ceren Durer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ceren Durer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ceren Durer. The network helps show where Ceren Durer may publish in the future.

Co-authorship network of co-authors of Ceren Durer

This figure shows the co-authorship network connecting the top 25 collaborators of Ceren Durer. A scholar is included among the top collaborators of Ceren Durer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ceren Durer. Ceren Durer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Durer, Ceren, et al.. (2022). Outcomes of combined ipilimumab/nivolumab in metastatic uveal melanoma: A prevalence meta-analysis.. Journal of Clinical Oncology. 40(16_suppl). 9534–9534.
2.
Kaseb, Hatem, Ceren Durer, Salman Fazal, & Hani M. Babiker. (2021). Plasma Cell Cancer. StatPearls.
3.
Durer, Seren, et al.. (2021). Adult-onset ornithine transcarbamylase deficiency as a rare cause of fatal hyperammonaemia. The Lancet. 398(10302). e11–e11. 4 indexed citations
4.
Durer, Seren, et al.. (2021). S1966 Sometimes “Wait and See” Policy Is the Best Cure for a Mass Found on Colonoscopy. The American Journal of Gastroenterology. 116(1). S860–S860.
5.
Durer, Ceren & Hani M. Babiker. (2020). Adult T Cell Leukemia. StatPearls. 1 indexed citations
6.
Durer, Ceren, et al.. (2020). Percutaneous Mechanical Pulmonary Thrombectomy in a Patient With Pulmonary Embolism as a First Presentation of COVID-19. Cureus. 12(8). e9506–e9506. 1 indexed citations
7.
Durer, Ceren, et al.. (2020). S1018 Fecal Microbiota Transplant Improves Cognitive Function in Patients With Hepatic Encephalopathy: A Systematic Review of Randomized Clinical Trial. The American Journal of Gastroenterology. 115(1). S519–S519. 1 indexed citations
8.
9.
Durer, Ceren, et al.. (2019). Seminoma metastasized to the prostate: A case report and literature review. Urology Case Reports. 29. 101096–101096. 3 indexed citations
10.
Durer, Ceren, Seren Durer, Sarah Lee, et al.. (2019). Treatment of relapsed multiple myeloma: Evidence-based recommendations. Blood Reviews. 39. 100616–100616. 42 indexed citations
11.
Durer, Ceren, et al.. (2019). Chilaiditi’s Sign: A Case Report. Cureus. 11(11). e6230–e6230. 6 indexed citations
12.
13.
14.
Kumar, Abhijeet, Muhammad Usman, Saad Ullah Malik, et al.. (2018). Treating Diffuse Large B Cell Lymphoma in the Very Old or Frail Patients. Current Treatment Options in Oncology. 19(10). 50–50. 10 indexed citations
15.
Khan, Ali Younas, Saad Ullah Malik, Warda Faridi, et al.. (2018). Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation. Biology of Blood and Marrow Transplantation. 25(1). 94–99. 127 indexed citations
16.
Malik, Saad Ullah, Ahmad Kamal, Syed Shams ul Hassan, et al.. (2018). Gene Therapy for Thalassemia and Sickle Cell Anemia Poses Acceptable Toxicity and Efficacy: Clinical Outcomes in Forty-Seven Cases. Blood. 132(Supplement 1). 2194–2194.
17.
Rafae, Abdul, Ali Younas Khan, Ceren Durer, et al.. (2018). Diagnostic and Prognostic Role of Fecal Calprotectin As a Biomarker for Gastrointestinal Graft Versus Host Disease: A Systematic Review of Literature. Blood. 132(Supplement 1). 5725–5725.
18.
Rafae, Abdul, Ahmad Kamal, Saad Ullah Malik, et al.. (2018). Presentation Patterns and Management Strategies for Central Nervous System Involvement in Multiple Myeloma: A Systematic Review of Literature. Blood. 132(Supplement 1). 1951–1951. 1 indexed citations
19.
Tariq, Muhammad Junaid, et al.. (2018). Efficacy, Toxicity and Targets for Adoptive Cellular Therapy in Multiple Myeloma: A Systematic Review. Blood. 132(Supplement 1). 5649–5649. 1 indexed citations
20.
Khan, Ali Younas, Muhammad Usman, Muhammad Junaid Tariq, et al.. (2018). The Use of Checkpoint Inhibitors before and after Allogeneic Stem Cell Transplantion: A Double-Edged Sword. Blood. 132(Supplement 1). 5722–5722. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Seren Durer Breakdown of academic impact, for papers by Christin B. DeStefano Breakdown of academic impact, for papers by Liya Ma Breakdown of academic impact, for papers by Kazunari Aoki Breakdown of academic impact, for papers by R. Erttmann Breakdown of academic impact, for papers by Trevor Shields Breakdown of academic impact, for papers by Ruemu Birhiray Breakdown of academic impact, for papers by L.F. Porrata Breakdown of academic impact, for papers by Teeraya Puavilai Breakdown of academic impact, for papers by Guy Cantin
Rankless by CCL
2026